Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06598241 · ClinicalTrials.gov registry record

Mirragen Diabetic Foot Ulcer Study

A clinical trial of Diabetic Foot Ulcer and Osteomyelitis Chronic, sponsored by The University of Texas Health Science Center at San Antonio.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT06598241: Recruiting study of Diabetic Foot Ulcer and Osteomyelitis Chronic, sponsored by The University of Texas Health Science Center at San Antonio.

NCT06598241 is a study of Diabetic Foot Ulcer and Osteomyelitis Chronic that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 20 participants, below the 255-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06598241, a study of Diabetic Foot Ulcer and Osteomyelitis Chronic, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

This study is being done to collect data from treatment of patients who have diabetes with non-healing foot wounds and are being treated with a resorbable and biocompatible borate-based bioactive glass fiber matrix. A borate-based bioactive glass fiber matrix is used to cover the ulcer for wound management. The primary objective of this study is to evaluate the safety and efficacy of the borate-based bioactive glass fiber matrix in the treatment of diabetic foot ulcers in a real-world setting. The secondary objective is to evaluate the clinical and financial benefits in terms of quality of healing, pain, and treatment cost.

Primary Outcome

Number of patients to achieve complete wound closure. Complete wound closure is defined as skin re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart.

Interventions

  • DEVICE Borate-base Bioactive Glass Fiber Matrix (BBGFM)

Study Locations (1)

Texas

  • UT Health Medical Arts and Research Center - San Antonio

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-09-20
Est. Completion 2026-11

What NCT06598241 shows while recruiting

NCT06598241 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 255-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (92% lower).

The record links to 2 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Borate-base Bioactive Glass Fiber Matrix (BBGFM) is the first listed.

NCT06598241 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06598241 about?

NCT06598241 is a clinical study titled "Mirragen Diabetic Foot Ulcer Study". This study is being done to collect data from treatment of patients who have diabetes with non-healing foot wounds and are being treated with a resorbable and biocompatible borate-based bioactive glass fiber matrix. A borate-based bioactive glass fiber matrix is used to cover the ulcer for wound man...

What is the current status of trial NCT06598241?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-09-20. Estimated completion is 2026-11.

What conditions does trial NCT06598241 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer, Osteomyelitis Chronic.

What interventions are being tested in trial NCT06598241?

The interventions under investigation include: Borate-base Bioactive Glass Fiber Matrix (BBGFM) (DEVICE).

Who is sponsoring clinical trial NCT06598241?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06598241 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06598241's enrollment target sits among peer trials

20 62nd of 67 higher than 5 of 67 other Diabetic Foot Ulcer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06598241, the US trial registry maintained by the National Library of Medicine. NCT06598241 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.